{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:51:18Z","timestamp":1770439878703,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.autrev.2012.11.012","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T15:20:58Z","timestamp":1354634458000},"page":"848-853","source":"Crossref","is-referenced-by-count":26,"title":["Standard immunosuppressive therapy of immune-mediated glomerular diseases"],"prefix":"10.1016","volume":"12","author":[{"given":"Antonello","family":"Pani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2012.11.012_bb0005","series-title":"Atlas of chronic kidney disease and end-stage renal disease in the United States","article-title":"USRDS 2009 annual data report","author":"Renal Data System","year":"2009"},{"key":"10.1016\/j.autrev.2012.11.012_bb0010","series-title":"Annual report\u2014treatment of end-stage organ failure in Canada, 1997 to 2006","author":"Canadian Institute for Health Information","year":"2008"},{"key":"10.1016\/j.autrev.2012.11.012_bb0015","series-title":"2006 Annual report of the Canadian Organ Replacement Registry Ottawa","article-title":"Treatment of end-stage organ failure in Canada, 1995 to 2004","author":"Canadian Institute of Health Information","year":"2007"},{"key":"10.1016\/j.autrev.2012.11.012_bb0020","article-title":"ERA-EDTA registry annual report","author":"ERA-EDTA Registry","year":"2007"},{"key":"10.1016\/j.autrev.2012.11.012_bb0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5414\/CNP70377","article-title":"Continental variations in IgA nephropathy among Asians","volume":"70","author":"Prakash","year":"2008","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2012.11.012_bb0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2005.06.011","article-title":"Lymphocytes on the front line of autoimmunity","volume":"5","author":"Youinou","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.11.012_bb0035","doi-asserted-by":"crossref","first-page":"A366","DOI":"10.1016\/j.autrev.2009.11.007","article-title":"Autoimmune kidney disease","volume":"9","author":"Segelmark","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2012.11.012_bb0040","doi-asserted-by":"crossref","first-page":"A259","DOI":"10.1016\/j.autrev.2009.12.002","article-title":"Definition of human autoimmunity\u2013autoantibodies versus autoimmune disease","volume":"9","author":"Lleo","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.11.012_bb0045","series-title":"Treatment of primary glomerulonephritis","first-page":"47","article-title":"Glucocorticoids and immunomodulating agents","author":"Ponticelli","year":"2009"},{"key":"10.1016\/j.autrev.2012.11.012_bb0050","series-title":"Brenner and Rector's the kidney","first-page":"1278","article-title":"Overview of therapy for glomerular disease","author":"Cattran","year":"2011"},{"issue":"3","key":"10.1016\/j.autrev.2012.11.012_bb0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.autrev.2010.09.020","article-title":"The role of autoimmunologists in investigating and treating autoimmune disorders","volume":"10","author":"Barabas","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2012.11.012_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.autrev.2011.07.006","article-title":"Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events","volume":"11","author":"Murdaca","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2012.11.012_bb0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"UK BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2012.11.012_bb0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.autrev.2009.03.010","article-title":"Prospective new biological therapies for rheumatoid arthritis","volume":"9","author":"Senolt","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.11.012_bb0080","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0272-6386(95)90437-9","article-title":"Increasing incidence of focal\u2013segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study","volume":"26","author":"Haas","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.autrev.2012.11.012_bb0085","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/ki.1994.311","article-title":"Treatment of the nephrotic syndrome associated with primary glomerulonephritis","volume":"46","author":"Ponticelli","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0090","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","article-title":"Proteinuria and the risk of developing end stage renal disease","volume":"63","author":"Iseki","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.autrev.2012.11.012_bb0095","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \u201cGruppo Italiano di Studi Epidemiologici in Nefrologia\u201d (GISEN)","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0100","first-page":"319","article-title":"Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials","volume":"237","author":"Vincent","year":"2003","journal-title":"Am Surg"},{"key":"10.1016\/j.autrev.2012.11.012_bb0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000187205","article-title":"Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?","volume":"63","author":"Bellomo","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.autrev.2012.11.012_bb0110","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophisiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Nephrol"},{"key":"10.1016\/j.autrev.2012.11.012_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Nephrol"},{"key":"10.1016\/j.autrev.2012.11.012_bb0120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephritic syndrome","volume":"44","author":"Ordonez","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2012.11.012_bb0130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","article-title":"Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children","volume":"8","author":"Tarshish","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2012.11.012_bb0135","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00467-008-0792-3","article-title":"Therapies for steroid-resistant nephrotic syndrome","volume":"23","author":"Hodson","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.autrev.2012.11.012_bb0140","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","article-title":"Cyclosporin in idiopatic syndrome. Workshop recommendations","volume":"72","author":"Cattran","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0145","series-title":"Treatment of primary glomerulonephritis","first-page":"179","article-title":"Minimal change nephropathy","author":"Coppo","year":"2009"},{"key":"10.1016\/j.autrev.2012.11.012_bb0150","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","article-title":"Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?","volume":"34","author":"Ponticelli","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2012.11.012_bb0155","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1046\/j.1523-1755.2002.00674.x","article-title":"Treatment of primary focal segmental glomerulosclerosis","volume":"62","author":"Korbet","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0160","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00063030-199912050-00002","article-title":"The place of cyclosporine in the management of primary nephrotic syndrome","volume":"12","author":"Ponticelli","year":"1999","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2012.11.012_bb0165","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid resistant focal glomerulosclerosis","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0170","unstructured":"Appel GB, Cattran DC. Treatment of primary focal segmental glomerulosclerosis. (UptoDate 2011 ott 20)."},{"issue":"3","key":"10.1016\/j.autrev.2012.11.012_bb0175","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1568-9972(02)00028-9","article-title":"The targets of nephritogenic antibodies in systemic autoimmune disorders","volume":"1","author":"Migliorini","year":"2002","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2012.11.012_bb0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.autrev.2005.04.002","article-title":"Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease","volume":"4","author":"Barabas","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.11.012_bb0185","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to antineutral endopeptidose antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.11.012_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phropholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"LH Js","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2012.11.012_bb0195","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.11.012_bb0200","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0205","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2012.11.012_bb0210","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","article-title":"Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer","volume":"39","author":"Koyana","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2012.11.012_bb0215","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"North America Nephrotic Syndrome study Group: cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0220","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2012.11.012_bb0225","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.2009121238","article-title":"ANCA disease: where is the field heading?","volume":"21","author":"Falk","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.autrev.2012.11.012_bb0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.autrev.2008.07.020","article-title":"Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to \u201cautoimmunity and infection\u201d","volume":"8","author":"Kallenberg","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2012.11.012_bb0235","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/BF00853446","article-title":"Renal vasculitis","volume":"2","author":"Cameron","year":"1988","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.autrev.2012.11.012_bb0240","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.11.012_bb0245","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.11.012_bb0250","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","article-title":"Cyclophosphamide therapy of severe systemic necrotizing vasculitis","volume":"301","author":"Fauci","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.11.012_bb0255","first-page":"181","article-title":"Vasculitis affecting the kidney: presentation, histopathology and long term outcome","volume":"210","author":"Serra","year":"1984","journal-title":"Q J of Med"},{"issue":"2","key":"10.1016\/j.autrev.2012.11.012_bb0260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00041552-199303000-00009","article-title":"Renal vasculities","volume":"2","author":"Balow","year":"1983","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.autrev.2012.11.012_bb0265","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.autrev.2010.07.009","article-title":"Microscopic polyangiitis: clinical presentation","volume":"9","author":"Villiger","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.11.012_bb0270","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.V7133","article-title":"Treatment response and relapse in antineutrophil cytoplasmatic auto-antibody-associated microscopic polyangitis and glomerulonephritis","volume":"7","author":"Nachman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2012.11.012_bb0275","first-page":"c182","article-title":"Rituximab in ANCA-associated vasculitis: fad or fact?","volume":"118","author":"Fervenza","year":"2011","journal-title":"Clin Pract"},{"issue":"6","key":"10.1016\/j.autrev.2012.11.012_bb0280","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide","volume":"128","author":"Cupps","year":"1982","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2012.11.012_bb0285","first-page":"391","article-title":"Activation of human B lymphocytes XII. Differential effects of in vitro cyclophosphamide on human lymphocyte sub populations involved in B-cell activation","volume":"39","author":"Stevenson","year":"1980","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.autrev.2012.11.012_bb0290","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1172\/JCI112922","article-title":"Selective effects of cyclophosphamide therapy on activation, proliferation and differentiation of human B cells","volume":"79","author":"Zhu","year":"1987","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.autrev.2012.11.012_bb0295","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2007.071936","article-title":"Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force","volume":"67","author":"Mukhtyar","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.11.012_bb0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.med.52.1.63","article-title":"Advances in the treatment of lupus nephritis","volume":"52","author":"Zimmermann","year":"2001","journal-title":"Ann Rev Med"},{"issue":"1","key":"10.1016\/j.autrev.2012.11.012_bb0305","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfq617","article-title":"The podocyte as a direct target of immunosuppressive agents","volume":"26","author":"Sch\u00f6nenberger","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.autrev.2012.11.012_bb0310","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-84-3-304","article-title":"Glucocorticosteroid therapy: mechanisms of action and clinical considerations","volume":"84","author":"Fauci","year":"1976","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2012.11.012_bb0315","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM197501302920504","article-title":"Effects of corticosteroid therapy on human monocyte function","volume":"292","author":"Rinehart","year":"1975","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2012.11.012_bb0320","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0091-6749(78)90101-X","article-title":"Corticosteroid effect on immunoglobulins","volume":"62","author":"Settipane","year":"1978","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2012.11.012_bb0325","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2012.11.012_bb0330","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00007890-197810000-00013","article-title":"Effect of corticosteroids on the human immune response. Suppression of mitogen-induced lymphocyte proliferation by \u201cpulse\u201d methylprednisolone","volume":"26","author":"Fan","year":"1978","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.autrev.2012.11.012_bb0335","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.autrev.2012.11.012_bb0340","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2008.07.010","article-title":"Use of glucocorticoids and risk of infections","volume":"8","author":"Cutolo","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"16","key":"10.1016\/j.autrev.2012.11.012_bb0345","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids","volume":"353","author":"Rhen","year":"2005","journal-title":"NEJM"},{"key":"10.1016\/j.autrev.2012.11.012_bb0350","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s004670000523","article-title":"A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children","volume":"16","author":"Latta","year":"2001","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2012.11.012_bb0355","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2005.10.001","article-title":"Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study","volume":"5","author":"Manger","year":"2006","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212002911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212002911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T12:18:00Z","timestamp":1687868280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997212002911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1568997212002911"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2012.11.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}